| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802870701012 | 287070101 | RANEXA PR.TAB 375MG/TAB BTx 60 σε BLISTERS (PVC/PVDC/ALU) (PVC/PVDC/ALU) | 48.65 | 51.04 | 64.93 |
| 05/2018 | 2802870702019 | 287070201 | RANEXA PR.TAB 500MG/TAB BTx 60 σε BLISTERS (PVC/PVDC/ALU) (PVC/PVDC/ALU) | 48.65 | 51.04 | 64.93 |
| 05/2018 | 2802870703016 | 287070301 | RANEXA PR.TAB 750MG/TAB BTx 60 σε BLISTERS (PVC/PVDC/ALU) (PVC/PVDC/ALU) | 48.65 | 51.04 | 64.93 |
For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.
The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.
In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.
Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.
7 hours
Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces.